Dainippon Sumitomo Pharma announces reorganization of its Research and Development
Osaka, Japan, March 4, 2013 - Dainippon Sumitomo Pharma Co., Ltd. (DSP) (Headquarters: Osaka, Japan; President: Masayo Tada) announces today that it will reorganize its Research and Development as follows.
1. Reorganization of Drug Research (effective April 1, 2013)
DSP will establish Innovative Drug Discovery Laboratories in order to create more innovative and efficient drug discovery from drug discovery to lead generation. In and after lead optimization phases, DSP will establish Drug Development Research Laboratories to promote swift and efficient advancement of research programs and projects. Additionally, in order to enter on a full scale into leading-edge medical fields, DSP will establish research groups within Innovative Drug Discovery Laboratories and the existing Genomic Science Laboratories which are dedicated to such fields like cell therapy and regenerative medicine.
Moreover, in order to improve the quality and speed of decision making, boost the comprehensive evaluation capability in safety and pharmacokinetic researches and to select drug candidates with higher added value through advanced evaluation technologies, DSP will establish the Pre-clinical Research Laboratories.
2. Reorganization of Drug Development (effective April 1, 2013)
In order to manage organizational operations in clinical development globally, DSP will establish Global Clinical Development (GCD) to integrate clinical development functions of DSP and Sunovion, and instate a Head of Global Clinical Development position in the U.S. We have reorganized Drug Development in Japan to mirror the organizational structure at Sunovion. In addition, we established Medical Affairs, assigned to maximize the value of development compounds and commercial products by establishing evidence based medicine.